Regorafenib monohydrate (Standard)

Overview

Regorafenib (monohydrate) (Standard) is the analytical standard of Regorafenib (monohydrate). This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC 50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ , Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Others | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Raf | Products > Signaling Pathways > RET | Products > Signaling Pathways > FGFR | Products > Signaling Pathways > c-Kit | Products > Signaling Pathways > Tie | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > PDGFR

Product Information

• Catalog No.: HY-10331AR
• CAS No.: 1019206-88-2
• Molecular Formula: C21H17ClF4N4O4
• Molecular Weight: 500.83
• Purity: 98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source